Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Interferon alfa-2a Pregnancy and Breastfeeding Warnings

Interferon alfa-2a is also known as: Roferon-A

Interferon alfa-2a Pregnancy Warnings

Interferon alfa-2a has been assigned to a pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. Doses of 20 to 500 times the human dose demonstrated a statistically significant increase in abortifacient activity in rhesus monkeys. There are no controlled data in human pregnancy. Decreases in serum estradiol and progesterone concentrations have been reported in women treated with human leukocyte interferon. Fertile women should not receive interferon alfa-2a unless they are using effective contraception.

See references

Interferon alfa-2a Breastfeeding Warnings

There are no data on the excretion of interferon alfa-2a into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from interferon alfa-2a, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Roferon-A Injection (interferon alfa-2a)." Roche Laboratories, Nutley, NJ.

References for breastfeeding information

  1. "Product Information. Roferon-A Injection (interferon alfa-2a)." Roche Laboratories, Nutley, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide